Dr. Luis Pinillos Ashton

Doctor in Medicine- Cayetano Heredia University
Radiation Oncologist- Oncosalud AUNA
Fellow of the Royal College of Radiology England FRCR
Emeritus Professor- Universidad Cayetano Heredia
Honorary Professor- Universidad Ricardo Palma
Founding President Oncosalud
Founding President ALATRO( Latín american radiotherapy society)
Former Peruvian Minister of Health
Former Director of INEN (National Cancer Institute)
Former President of CLACTA (Latín American Coalition for Tobacco Control)
Former member Medical Committee ICRP
Former Peruvian representative to UNSCEAR
Founding President of COLAT. (anti tobacco national coalition)
Academician of the Peruvian National Academy of Medicine

Javier Cortés, MD PhD
• International Breast Cancer Center (IBCC), Barcelona, Spain
• Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
• Medica Scentia Innovation Research (MedSIR), Barcelona, Spain & New Jersey, US
Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996, specialist in Medical Oncology by the Clínica Universitaria de Navarra, and awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology. In addition he was the Head of the Breast Cancer Program from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. Dr. Cortes was the Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, from 2011 to September 2020. He has been Senior Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology from 2011 to February 2022.
Dr. Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials.
In addition to his medical specialties, he has two master degrees in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
He has contributed to over 430 peer-reviewed publications, especially about breast tumours and new drugs and more than 800 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is an ad hoc reviewer of various oncology journals, including, New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology or Journal of Clinical Oncology, among many others
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society for Medical Oncology (ESMO), of the Scientific Committee of the European Breast Cancer Conference (EBCC), has been chair for breast cancer at the ESMO 2020 congress, and co-chair of the same section in the congress of the American Association for Cancer Research (AACR) 2020, as well as the immunotherapy area of the AACR 2021 congress. He is a member of the expert panel that develops the treatment guidelines for metastatic breast cancer of the European Society for Medical Oncology, member of the ABC Conference, member of the ASCO International Affairs Committee, member of the executive panel in charge of SABCS Strategic Planning, and co-organizer of the Annual Congress of Controversies in Breast Cancer (CoBrCa).
In addition, according to the American Expertscape 2023 ranking, he is considered the world’s leading expert on HER2+ and fourth world oncologist with the greatest expertise in breast cancer and in 2022 and 2023 was identified as Clarivate™ world’s most influential researchers.

Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Ronald LimonMD MSc
Clinical Oncologist
Master in Molecular Oncology Universidad Rey Juan Carlos Madrid – España
Genetics and – Cancer Genetics Harvard University
Immunology and Immuno-Oncology Harvard University
Investigator and member of different scientific societies
Expertise field: Breast Cancer

Antonio Llombart Cussac MD, PhD
Medical doctor and specialist in medical oncology. He is currently head of the Medical Oncology Service at the Arnau de Vilanova Hospital in Valencia and full professor of Clinical Oncology at the Catholic University of Valencia.
With more than 5 years of academic and research training in France and the United States, he is an international expert in breast cancer, with more than 100 indexed publications in the last 5 years. Involved in different Breast Cancer research groups, he is a founding partner and senior-expert at MedSIR (2012), a company dedicated to promoting high-impact clinical research in collaboration with the scientific community, pharmaceutical and biotech companies.
He has been secretary of the Spanish Society of Medical Oncology (1998-2002 and 2012-2016), scientific coordinator (2006-2010) and past-president (2010-2014) of the SOLTI Research Group. He is a member of different scientific societies (SEOM, ESMO, ASCO, AACR, ECO). Since 2017 he has been a reference academician of the Royal Academy of Medicine and Sciences of the Valencian Community.

Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.

Dr. David Antonio Martínez Pérez
Radiation Oncologist – Regional Integrator of Methodologies and Practices in Radiotherapy at AUNA
Program Director of the Preceptorship in Interventional Radiotherapy / Brachytherapy at AUNA
Director of Education and Training for LATAM at the Rayos Contra Cancer Foundation

Stuart McIntosh is Professor of Surgical Oncology at Queen’s University in Belfast, and a consultant oncoplastic breast surgeon at Belfast City Hospital.
Stuart is an experienced clinical trialist, with a particular interest in neoadjuvant, peri-surgical and treatment de-escalation studies, and is Chief Investigator for the UK SMALL trial, as well as holding surgical leadership roles in several other trials. He is also one of the Royal College of Surgeons Surgical Specialty Leads for Breast Surgery, responsible for supporting the development and delivery of breast cancer surgical trials nationally. Additionally, he chairs the Northern Ireland Cancer Trials Network, responsible for the delivery of cancer trials across the five cancer hospitals in Northern Ireland. Stuart’s laboratory research interests include the DNA damage driven immune response in breast cancer.

Dr. Henry Gomez Moreno

Medical Oncologist- Clinica Oncosalud AUNA
Associate Research Professor- Research Institute of Biomedical Sciences- Universidad Ricardo Palma
Profesor- Universidad Cayetano Heredia
Scientific Advisor- AUNA Ideas
Member of the Latin American Cooperative Oncology Group (LACOG)
Principal Investigator for the International Breast Cancer Study Group (IBCSG), the Breast Cancer Group (BIG) and the Eastern Cooperative Oncology Group (ECOG)
Member of the National Academy of Medicine of Peru
Distinguished Researcher by the National Council of Science, Technology and Technological Innovation (Concytec)

LIA PAMELA REBAZA

VASQUEZCIRUJANO ONCOLOGO DE MAMA,PARTES BLANDAS Y PIEL
CMP: 53369 RNE : 29708 / 24633Educación

Experiencia
2017- Hasta la Fecha – Médico Cirujano Oncólogo de mama partes blandas y piel Clinica Oncosalud – Auna
2023- Hasta la Fecha – Médico Cirujano Oncólogo de mama partes blandas y piel Clinica Guardia Civil – Auna
2016-2020 – Médico Prenvención Oncologica Oncosalud . Auna
2013- 2016 – Medico Fellow en cirugía oncológica de mamas, partes blandas y piel
Sociedades
Sociedad Peruana de Cancerología Sociedad Peruana de Mastologia
Sociedad Peruana de Cirugia Oncologica
Eubreast (European Breast Cancer Association of Surgical Trial)

Ponencias
VII Best of San Antonio Breast Cancer Symposium® PERÚ Marzo 2025 – Ponente
Ponente del IX Congreso Nacional de Mastología – Sociedad
Peruana de Mastologia . 27-28 de Setiembre 2024
VII Best of San Antonio Breast Cancer Symposium® PERÚ Marzo 2024 – Ponente
Curso Internacional Hands – on de Cirugia Oncoplastica mamaria
Agosto , Setiembre , Octubre 2023 – Co- organizadora Ponente y miembro del Comité organizador del XIII Congreso Nacional de Mastología , Sociedad de Mastologia . Noviembre
Ponente Best of San Antonio Breast Cancer Simposium Marzo 2020

Nirmala Pathmanathan

Nirmala Pathmanathan is a specialist breast pathologist. She is the Director of the Westmead Breast Cancer Institute in Sydney (a multidisciplinary breast diagnostic and treatment centre servicing Western Sydney), a specialist breast pathologist with Douglass Hanly Moir Pathology in Sydney and the Director for BreastScreen Program for Sydney West. She is a Clinical Associate Professor with the University of Sydney, Faculty of Medicine and Health.

Shelley Potter PhD FHEA FRCS
Shelley Potter is Professor of Surgical Oncology at Bristol Medical School and Consultant Oncoplastic Breast Surgeon at North Bristol NHS Trust.
Her research interests focus on improving outcomes for women with breast cancer through the development and delivery of high-quality patient-centred research. She is an experienced researcher who had led several national and international collaborative oncoplastic and reconstructive breast surgical projects including the iBRA and TEAM studies and is currently Chief Investigator for Brighter, ANTHEM and Pre-BRA. Recent work has focused on optimisation of breast cancer treatment.
Her leadership national roles include Royal College of Surgeons of England Surgical Specialty Lead for Breast Surgery, Chair of iBRA-NET and Secretary to the British Breast Group.

Dr. Karla Sepulveda is a Professor of Radiology at Baylor College of Medicine and Medical Director of Breast Imaging at Baylor St. Luke’s Medical Center in Houston. TX. She holds the Pat Korell Endowed Professorship of Breast Imaging. Dr. Sepulveda completed her fellowship in Breast Imaging at MD Anderson Cancer Center. She is active in the American College of Radiology and Texas Radiological Society and uses this work to advocate for high value, multidisciplinary care for breast cancer patients. Her areas of professional interest include healthcare innovation, the role of radiology in precision oncology, and applications of artificial intelligence in breast imaging.

Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 20 PhD or research MD students and currently has 4 students completing PhDs. The impact of over 200 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research, South West Oncology Group and Translational Breast Cancer Research Consortium.